Cargando…
In Silico and In Vitro studies of taiwan chingguan yihau (NRICM101) on TNF-α/IL-1β-induced human lung cells
COVID-19 pandemic has been a global outbreak of coronavirus (SARS-CoV-2 virus) since 2019. Taiwan Chingguan Yihau (NRICM101) is the first traditional Chinese medicine (TCM) classic herbal formula and is widely used for COVID-19 patients in Taiwan and more than 50 nations. This study is to investigat...
Autores principales: | Cheng, Yih-Dih, Lu, Chi-Cheng, Hsu, Yuan-Man, Tsai, Fuu-Jen, Bau, Da-Tian, Tsai, Shih-Chang, Cheng, Ching-Chang, Lin, Jen-Jyh, Huang, Yuang-Yu, Juan, Yu-Ning, Chiu, Yu-Jen, Kuo, Sheng-Chu, Yang, Jai-Sing, Wu, Lii-Tzu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
China Medical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629402/ https://www.ncbi.nlm.nih.gov/pubmed/36381194 http://dx.doi.org/10.37796/2211-8039.1378 |
Ejemplares similares
-
Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101)
por: Su, Yi-Chang, et al.
Publicado: (2022) -
The development and application of NRICM101 and NRICM102 for the treatment of COVID-19
por: Ho, Shung-Tai, et al.
Publicado: (2023) -
Analysis of COVID-19 prevention and treatment in Taiwan
por: Chiu, Yu-Jen, et al.
Publicado: (2021) -
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply
por: Lin, Sunny Jui-Shan, et al.
Publicado: (2022) -
Treating COVID-19 with NRICM101 and NRICM102 – Author’s reply 3
por: Tseng, Yu-Hwei, et al.
Publicado: (2022)